Role of Proteasomes in a Dermatological Autoimmune Disease: Bullous Pemphigoid

Inclusion Criteria: * The patient must have given his/her informed and signed consent * The patient must be insured or beneficiary of a health insurance plan * The patient is not taking systemic treatment * The patient has not been treated with topical steroids for more than 15 days. For the bullous pemphigoid group: * clinical signs: erythematous-based lesions, especially on flexion areas of the arms and legs, not afflicting mucous membranes, and without atrophic scaring * histology: without epidermal acantholysis For the pemphigus group: * patient with pemphigus For the lupus group: * systemic lupus patients: presence of the 4 diagnostic criteria for systemic lupus erythematosus as defined by the American College of Rheumatology (amended 1997) * or characteristics of subacute cutaneous lupus: clinical, histological and immunological (anti-SSa) * or clinical and histological characteristics of chronic lupus For the control group: * hospitalized patients with no history of auto-immune, inflammatory or evolving neoplastic disease Exclusion Criteria: * The patient is participating in another study * The patient is in an exclusion period determined by a previous study * The patient is under judicial protection, under tutorship or curatorship * The patient refuses to sign the consent * It is impossible to correctly inform the patient * The patient is pregnant, parturient, or breastfeeding For patients with bullous pemphigoid, pemphigus or lupus: * The patient is taking systemic treatment * The patient has been taking topical steroids for more than 15 days. For the controls: * autoimmune disease * inflammatory disease * evolving neoplastic disease * surgery during the last 6 months